Genitourinary Cancer News

First-line pembrolizumab plus axitinib extended survival among patients with advanced renal cell carcinoma, according to updated results of the randomized phase 3 KEYNOTE-426 study presented during the ASCO20 Virtual Scientific Program.

The FDA approved several therapies for oncology or hematology indications.

The FDA granted breakthrough therapy status to two cancer therapies.

The FDA granted fast track designation to several therapies in development for hematology or oncology indications.

ASCO announced the recipients of several awards intended to honor researchers and other leaders in oncology who strive to transform cancer care.

The FDA approved an additional recommended dosage of pembrolizumab, authorizing its use at 400 mg every 6 weeks.

A cell-free DNA multicancer early detection test demonstrated an ability to predict cancer and the tissue of origin in individuals with clinical suspicion of cancer, according to results of the Circulating Cell-free Genome Atlas study presented at the virtual American Association for Cancer Research Annual Meeting.

The FDA granted breakthrough therapy designation to three agents in development for oncology indications.

The combination of gemcitabine and platinum chemotherapy administered within 90 days after nephroureterectomy significantly extended DFS among patients with locally advanced upper tract urothelial carcinoma, according to results of the randomized phase 3 POUT trial published in The Lancet.

The FDA approved mitomycin gel for the treatment of low-grade upper tract urothelial cancer.